Search Team

Search by Last Name
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Background

Cheryl Wang’s intellectual property litigation practice spans a wide range of technology, including life sciences, pharmaceuticals, biotechnology, software, hardware, and medical devices. Ms. Wang has worked on a variety of technologies, including pharmaceutical formulations, antibodies, biologics, immunotherapy, CRISPR, sleep apnea devices, encryption hardware, and mobile data. Ms. Wang has experience from pre-suit diligence to dispositive hearing, including analyzing patent portfolios, conducting research and discovery, briefing injunctive and claim construction issues, assisting depositions and expert reports, and preparing witnesses for trial testimony. Ms. Wang has worked on district court, ITC, arbitration, and Federal Circuit cases.

Ms. Wang is committed to pro bono and diversity. She represents indigent pro bono clients and work on high-impact policy litigation.

Before joining Fish, Ms. Wang worked in nanotechnology and small molecule pharmaceutical development. She has also clerked for Judge Tamila E. Ipema and Judge Joel Pressman, and worked as a legal research specialist and treatise editor.

Education

University of Virginia School of Law 2018
J.D.
Articles Editor, Virginia Tax Review


University of California, San Diego 2014
Chemistry, minor in Psychology, B.S.

Admissions

  • California 2018

Language

  • English
  • Mandarin Chinese

Other Distinctions

Selected Publications

Ms. Wang is a contributing author to Fish’s IP Law Essentials.

How Biosimilars Are Approved and Litigated: Patent Dance Timeline,” co-authored with Kayleigh McGlynn, Grant Rice, Jenny Shmuel, Nicole Williams, Fish IP Law Essentials Blog (August 12, 2020).

FDA Seeks to Modernize the Orange Book,” co-authored with Geoff Biegler and Megan Chacon, Fish Litigation Blog (June 22, 2020).

Introduction to Biologics and Biosimilars,” co-authored with Michael Anderson, Kayleigh McGlynn, Tracea Rice, Jenny Shmuel, Fish IP Law Essentials Blog (June 4, 2020).

Overview of Approaches to Compulsory Licensing,” co-authored with Brian Coggio and Sushil Iyer, Fish IP Law Essentials Blog (May 21, 2020).

Where Juries Come From,” co-authored with Alexander Kykta, Douglas McCann, Katherine Reardon, Fish IP Law Essentials Blog (May 1, 2020).

A Biosimilar’s Guide to the BPCIA Patent Dance: Five Key Questions for Every Biosimilar Applicant to Consider,” co-authored with Jenny Shmuel, Michael Anderson, Kayleigh McGlynn, Grant Rice, Fish Litigation Blog (April 20, 2020).

Insulin and Other Biological Products Previously Regulated as “Drugs” Transition to Biologics Regulation on March 23, 2020,” co-authored with Jenny Shmuel and Michael Anderson, Fish Litigation Blog (March 20, 2020).

Increasing Competition in the Biologic Market Through Truthful Advertising,” co-authored with Jenny Shmuel, Fish Litigation Blog (February 7, 2020).

What's trending with Cheryl

Filter by
Fish Litigation Blog
April 20, 2020
A Biosimilar’s Guide to the BPCIA Patent Dance: Five Key Questions for Every Biosimilar Applicant to Consider
Authors: Kayleigh E. McGlynn, Cheryl Wang, Grant T. Rice, Ph.D., Jenny Shmuel, Ph.D.
IP Litigation
Life Sciences
Fish Litigation Blog
August 12, 2020
How Biosimilars Are Approved and Litigated: Patent Dance Timeline
Authors: Kayleigh E. McGlynn, Cheryl Wang, Nicole Williams, Grant T. Rice, Ph.D., Jenny Shmuel, Ph.D.
IP Law Essentials
Fish Litigation Blog
July 10, 2020
Chief Judge Stark Dismisses Hatch-Waxman Case after Paragraph IV to Paragraph III Conversion
Legal Alerts
Blogs
Fish Litigation Blog
June 22, 2020
FDA Seeks to Modernize the Orange Book
Authors: Cheryl Wang, Megan A. Chacon, Geoffrey D. Biegler
Uncategorized
Fish Litigation Blog
June 4, 2020
Introduction to Biologics and Biosimilars
Blogs
IP Law Essentials
Fish Litigation Blog
May 21, 2020
Overview of Approaches to Compulsory Licensing
Blogs
IP Law Essentials
Fish Litigation Blog
May 1, 2020
Where Juries Come From
Authors: Cheryl Wang, Alexander Kykta, Katherine Reardon, Douglas E. McCann
IP Law Essentials
Fish Litigation Blog
March 20, 2020
Insulin and Other Biological Products Previously Regulated as “Drugs” Transition to Biologics Regulation on March 23, 2020
Authors: Cheryl Wang, Jenny Shmuel, Ph.D.
Life Sciences
Fish Litigation Blog
February 7, 2020
Increasing Competition in the Biologic Market Through Truthful Advertising
Authors: Cheryl Wang, Jenny Shmuel, Ph.D.
Life Sciences
News
January 16, 2019
Fish & Richardson Grows Firm With 14 Associates
Press Release
News
load more topics